Eli Lilly obesity drug candidate Bimagrumab showed fat-loss benefits in a Phase 2B trial, especially when combined with semaglutide. While Leerink Partners called the results compelling, analysts from Jefferies and Wolfe flagged safety concerns and await more data. Lilly stock is flat in 2025.